Is Nabriva Therapeutics PLC halal to invest in?

According to Musaffa's Shariah screening methodology, Nabriva Therapeutics PLC (NBRVF) is currently classified as NOT COVERED as of May 2026. The classification is based on an evaluation of the company's business activities and financial ratios to determine whether it meets Islamic investment guidelines.

Is Nabriva Therapeutics PLC a Shariah-compliant stock?

A stock is Shariah-compliant if the company operates in permissible business activities and meets Islamic financial screening thresholds. Musaffa analyzes Nabriva Therapeutics PLC using these criteria to determine its compliance status.

Can Muslims buy shares of Nabriva Therapeutics PLC?

Muslim investors may consider investing in Nabriva Therapeutics PLC if it meets Shariah compliance standards. Investors typically review the company's business activities, debt levels, and non-permissible income before making a decision.

Why is Nabriva Therapeutics PLC classified as NOT COVERED?

Musaffa determines the Shariah status of Nabriva Therapeutics PLC by analyzing whether the company's core business operations are permissible and whether its financial ratios fall within accepted Islamic thresholds.

How often is the Shariah compliance for Nabriva Therapeutics PLC updated?

The Shariah compliance status of Nabriva Therapeutics PLC may be updated periodically when new financial statements, earnings reports, or business activity information become available.

Can a halal stock like Nabriva Therapeutics PLC become non-compliant?

Yes. A stock that is currently Shariah-compliant may become non-compliant if the company's financial ratios exceed Shariah thresholds or its business activities change.

Where can I check the Shariah status of Nabriva Therapeutics PLC?

You can check the latest Shariah compliance status of Nabriva Therapeutics PLC on Musaffa's stock page, where screening results and key financial indicators are updated to help Muslim investors make informed decisions.

Analyst's Ratings for Nabriva Therapeutics PLC (NBRVF)

Based on 8 analysts giving stock ratings to Nabriva Therapeutics PLC in the past 3 months

Strong
SellSellHoldBuyStrong
Buy

Strong Buy

Buy

Hold

Sell

Strong Sell

Nabriva Therapeutics PLC. Stock Analysis NBRVF

United States Health Care Nano Cap

Nabriva Therapeutics Plc is a biopharmaceutical company, which engages in the commercialization and development of novel anti-infective agents to treat infections. The firm's product, XENLETA (lefamulin injection, lefamulin tablets), is the first systemic pleuromutilin antibiotic for community-acquired bacterial pneumonia (CABP). XENLETA is designed to inhibit the synthesis of a specific protein on the bacterial ribosome, required for bacterial growth, by binding with high affinity and specificity at molecular targets different from those of other available antibiotic classes, causing cell death.

Key Statistics of Nabriva Therapeutics PLC (NBRVF)

Key statistics in the stock market are essential financial indicators that measure a company's performance, valuation, profitability, and risk.

Today's Range

$0.00$0.00

Today's Open

$0.00

Volume

168.00

P/E Ratio (TTM)

52 Week Range

$0.00$0.00

Market Cap

3.20

Avg. Volume

690.67

Dividend Yield

Financial Metrics & Statements of Nabriva Therapeutics PLC (NBRVF)

FAQ's for Nabriva Therapeutics PLC (NBRVF)

According to Musaffa’s Shariah screening methodology, Nabriva Therapeutics PLC (NBRVF) is currently classified as NOT COVERED as of May 2026. The classification is based on an evaluation of the company’s business activities and financial ratios to determine whether it meets Islamic investment guidelines.